Arca
Skip to content

Succinylcholine Chloride

ANDA 211346, held by Fresenius Kabi USA. Succinylcholine Chloride.

  • First approved: Nov 20, 2020
  • Review: Standard
  • Supplements approved: 3
  • Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 4 submissions below
DateSubmissionStatusDocuments
Nov 20, 2020Original applicationApprovedNone posted

Products

1 strengths and forms
ProductActive ingredientMarketing
Succinylcholine Chloride20MG/ML · injectable;injectionSuccinylcholine ChlorideRx
All 4 submissions, including labeling and manufacturing supplements
DateSubmissionStatusDocuments
Mar 9, 2024Supplement 3Labeling · Standard reviewApprovedNone posted
Sep 21, 2022Supplement 2Labeling · Standard reviewApprovedNone posted
Mar 16, 2022Supplement 1Labeling · Standard reviewApprovedNone posted
Nov 20, 2020Original applicationApprovedNone posted

Identifiers

Application
ANDA 211346

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed weekly; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.